Your browser doesn't support javascript.
Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs.
Mroz, Magdalena; Mucka, Szymon; Miodonska, Martyna; Ziolkowska, Dominika; Hadas, Ewa; Bozek, Andrzej.
  • Mroz M; Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland.
  • Mucka S; Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland.
  • Miodonska M; Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland.
  • Ziolkowska D; Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland.
  • Hadas E; Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland.
  • Bozek A; Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland.
Medicina (Kaunas) ; 57(9)2021 Aug 27.
Article in English | MEDLINE | ID: covidwho-1374459
ABSTRACT
Background and

objectives:

Biological treatment is an important and effective therapy for psoriasis. During the COVID-19 pandemic, it remains unclear whether this type of therapy affects the course of SARS-CoV-2 infection. The aim of the study was to observe patients with psoriasis undergoing biological or other systemic treatment in relation to the impact of SARS-CoV-2 infection on the course of psoriasis and the COVID-19 disease itself. Materials and

methods:

A one-year observational study included 57 patients with diagnosed psoriasis who qualified for biological treatment and a group of 68 similar patients who were administered a different systemic treatment. Patients were analyzed monthly for psoriasis (including Psoriasis Area Severity Index (PASI) assessment) and constantly for SARS-CoV-2 infection (telephone contact). Cases of COVID-19 were confirmed by Polymerase Chain Reaction (PCR) at the study center.

Results:

SARS-CoV-2 infection was confirmed by a positive Real Time Polymerase Chain Reaction (RT-PCR) test in eight patients (14.0%) with psoriasis on biological therapy. None of the cases in this group required hospitalization for COVID-19. Similar data were obtained in the control group. Specifically, 11 (16%) patients were confirmed to be infected with SARS-CoV-2. These results were statistically comparable (p > 0.05). In the group of patients undergoing biological treatment, six (75%) of eight patients developed an exacerbation of psoriasis during SARS-CoV-2 infection, and similar results were noted in the control group, with eight (72%) patients experiencing an exacerbation of psoriasis.

Conclusions:

Patients with psoriasis who were administered biological treatment or other systemic therapy may experience a mild course of SARS-CoV-2 infection but might also experience a temporary exacerbation of skin lesions.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis / Biological Products / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: Medicina57090881

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis / Biological Products / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: Medicina57090881